Both in Pharmaceuticals
Roivant Sciences vs Alnylam Pharmaceuticals
Over the past year ROIV returned +85.1% and ALNY returned −63.1%; their daily moves had a correlation of 0.02.
ROIV +85.1% ALNY −63.1%Growth of $1, one year, split-adjusted
| Metric | ROIV | ALNY |
|---|---|---|
| Price | $36.27 | $160.17 |
| Market cap | $26.20B | $21.45B |
| Today | −1.73% | −2.93% |
| 1 month | +1.5% | −27.1% |
| 6 months | +27.9% | −46.2% |
| Year to date | +67.1% | −59.7% |
| 1 year | +85.2% | −64.4% |
| Revenue growth (YoY) | −33.5% | +16.7% |
| Gross margin | 100.0% | 75.2% |
| Net margin | −13164.8% | 148.6% |
| P/E (TTM) | — | 7.9× |
| Price / sales | 3,478.3× | 4.3× |
| Net cash | $3.84B | $2.57B |
| Dividend yield | — | — |
| Volatility (60d) | 48.8% | 72.6% |
| Short % of float | 8.0% | 4.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).